Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baijun Zhou

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|September 25, 2025
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus NephritisApril Jorge, Aakash V Patel, Baijun Zhou, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 11, 2025
Acute rhinosinusitis in patients with primary and secondary hypogammaglobulinemia due to B-cell targeted therapy and CAR T-cell therapyTejas S Athni, Lingxiao Zhang, Baijun Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2023
Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus ErythematosusEmma Materne, Hyon Choi, Baijun Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2023
ReplyApril M Jorge, Emma Materne, Baijun Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2024
Hydroxychloroquine Dose and Hospitalizations for Active LupusJacquelyn Nestor, Hyon Choi, Christian Mancini, et al.
JAMA|September 16, 2022
Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus FlaresApril M Jorge, Christian Mancini, Baijun Zhou, et al.
JAMA Network Open|May 9, 2024
Risk Factors for Hydroxychloroquine Retinopathy and Its SubtypesApril M Jorge, Ronald B Melles, Michael F Marmor, et al.
Journal of Clinical Medicine|March 28, 2026
Genetic Variations in the M6A Modification Pathway as Potential Predictors of Imatinib Secondary Resistance in Gastrointestinal Stromal TumorsBaijun Zhou, Zhenchong Chen, Gengyi Zhang, et al.
Frontiers in Immunology|August 14, 2023
Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiencyMegha Tandon, Daniel V DiGiacomo, Baijun Zhou, et al.
Annals of Internal Medicine|January 16, 2023
Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort StudyRonald B Melles, April M Jorge, Michael F Marmor, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Arthritis & Rheumatology (Hoboken, N.J.)|September 25, 2025
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus NephritisApril Jorge, Aakash V Patel, Baijun Zhou, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 11, 2025
Acute rhinosinusitis in patients with primary and secondary hypogammaglobulinemia due to B-cell targeted therapy and CAR T-cell therapyTejas S Athni, Lingxiao Zhang, Baijun Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2023
Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus ErythematosusEmma Materne, Hyon Choi, Baijun Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2023
ReplyApril M Jorge, Emma Materne, Baijun Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2024
Hydroxychloroquine Dose and Hospitalizations for Active LupusJacquelyn Nestor, Hyon Choi, Christian Mancini, et al.
JAMA|September 16, 2022
Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus FlaresApril M Jorge, Christian Mancini, Baijun Zhou, et al.
JAMA Network Open|May 9, 2024
Risk Factors for Hydroxychloroquine Retinopathy and Its SubtypesApril M Jorge, Ronald B Melles, Michael F Marmor, et al.
Journal of Clinical Medicine|March 28, 2026
Genetic Variations in the M6A Modification Pathway as Potential Predictors of Imatinib Secondary Resistance in Gastrointestinal Stromal TumorsBaijun Zhou, Zhenchong Chen, Gengyi Zhang, et al.
Frontiers in Immunology|August 14, 2023
Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiencyMegha Tandon, Daniel V DiGiacomo, Baijun Zhou, et al.
Annals of Internal Medicine|January 16, 2023
Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort StudyRonald B Melles, April M Jorge, Michael F Marmor, et al.
Pageof 2